Bonton

Quick links to important sections

Bonton

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bonton

Property Description
Active ingredient Lorazepam
Forms Tablets, Solution for Injection
Pharmacological class Benzodiazepine
General purpose Anxiolytic and Sedative-Hypnotic
Origin Synthetic Compound

Bonton is the trade name for a specific formulation containing the active substance Lorazepam. This medication is clinically recognized for its ability to affect the central nervous system (CNS) and is classified pharmacologically as a benzodiazepine. As a synthetic compound, Lorazepam is structurally defined and highly studied. The compound’s profile is distinct, being recognized as a potent, short-to-intermediate-acting agent within its class. The primary differentiating factor for Bonton is its presentation as a product manufactured under quality controls, offering reliable formulations of Lorazepam for prescription use.

Composition and Available Preparations

Bonton is a single-ingredient product, featuring only Lorazepam as the therapeutically active compound. The medication is presented in multiple dosage forms, notably as the oral tablet and as a solution for injection suitable for parenteral administration. This variety is a key feature, enabling its use for planned management via oral administration or for immediate stabilization via injection, where a rapid onset of effect is necessary. The injection solution utilizes a specific liquid solvent vehicle to ensure stability and proper delivery.

General Purpose: A Calming and Stabilizing Agent

The general purpose of Bonton is rooted in its pharmacological action: to provide a calming and stabilizing effect on the body and mind. Pharmacological studies confirm that Lorazepam works by enhancing the inhibitory effects of the neurotransmitter GABA, which effectively acts as the brain’s natural 'brake'. This foundational mechanism allows the drug to rapidly reduce excessive neuronal activity, mitigating states of acute agitation or heightened nervousness. The resultant effect defines Bonton as a potent anxiolytic and sedative-hypnotic agent.

Regulatory References

  1. solution for injection
  2. enhances the inhibitory effects of the neurotransmitter GABA

What side effects are possible with Bonton?

Possible side effects and safety information

Bonton's safety profile is formally documented by government regulatory agencies, establishing specific categories of possible adverse reactions and critical safety constraints. The medication's primary documented effects relate to the Central Nervous System (CNS), which dictates the classification of its most frequently observed side effects.


Frequency Classification of Adverse Reactions

The most commonly documented adverse reactions are linked to CNS depressant activity. The official regulatory classification defines these effects based on observed frequency:

  • Very Common (Affecting ge10%): Drowsiness (somnolence), Sedation.
  • Common (Affecting 1% to 10%): Dizziness, Ataxia (impaired coordination), Fatigue, Muscular weakness.
  • Rare / Very Rare: Adverse effects such as confusion, depression (worsening or emergence), changes in salivation, abnormal liver function tests, and rare cases of jaundice have been officially reported.

Serious Safety Constraints and Risks

Specific serious adverse reactions and safety limitations are detailed in official prescribing information. These risks, while less frequent, are considered clinically significant:

  • Respiratory Risk: The concurrent use of Bonton with other CNS depressants, particularly opioids, is associated with a risk of profound sedation, respiratory depression, coma, and death.
  • Dependence and Withdrawal: The medication carries a documented risk of physical and psychological dependence. Regulatory documents note that the risk increases with higher doses and prolonged use, and abrupt discontinuation may trigger life-threatening acute withdrawal reactions, including seizures.
  • Population-Specific Considerations: Elderly or debilitated patients are noted as being more susceptible to the drug's sedative effects. Furthermore, caution is officially advised when used in patients with severe hepatic insufficiency or compromised respiratory function.

These safety classifications define the medicine's risk profile based on evidence established by authoritative health bodies.

Overdose and Emergency Response

Bonton Overdose and When to Seek Help

The official regulatory documents define the overdose profile of Bonton (Lorazepam) based on progressive central nervous system (CNS) depression, which dictates the required emergency response.

Feature Official Regulatory Statements
Documented Overdose Presentations Symptoms may include drowsiness, confusion, extreme lethargy, unsteadiness (ataxia), slurred speech, and reduced muscle tone (hypotonia).
Life-Threatening Outcomes The most severe documented outcomes are profound sedation leading to coma, respiratory depression (which may be fatal), and significant hypotension.
Dose-Related Factors The risk of severe, life-threatening outcomes, including respiratory arrest, is substantially increased when the drug is co-ingested with other CNS depressants, notably opioids or alcohol.
Population-Specific Notes Elderly patients are documented as being more susceptible to severe sedative effects and associated complications, such as unsteadiness. Paradoxical reactions have also been reported.
Emergency Actions Required Seek immediate medical attention for all suspected overdoses. Contact emergency services immediately upon the appearance of severe signs like shallow breathing, unresponsiveness, or inability to be awakened. Hospital monitoring is required for persistent signs of intoxication.

Official Overdose Management Statements:

  • Symptomatic and supportive treatment is the documented mainstay for managing intoxication.
  • Airway management is a critical component of supportive care.
  • The specific benzodiazepine antagonist, Flumazenil, is noted to be available, although its administration is subject to regulatory constraints and specialized monitoring.

Connection to the overall overdose profile: The regulatory documents detail a clear escalation of symptoms from mild CNS depression to life-threatening respiratory compromise, which explicitly mandates seeking immediate medical help. The profile emphasizes management through supportive care and close observation until intoxication resolves.

Therapeutic Uses of Bonton

Quick Facts

  • Condition Supported: Osteoporosis in postmenopausal women.
  • Therapeutic Goal: Support maintenance of bone mineral density.
  • Clinical Effect: May contribute to a reduction in the occurrence of certain fractures.

What Bonton Treats: Main Uses and Benefits

Bonton is an approved prescription medication utilized in the management of osteoporosis in women who have completed menopause. The primary objective of therapy is to support bone mineral density in this patient population.

Therapy with Bonton is a component of a complete treatment plan and is intended to favorably influence bone health parameters. Clinical data has demonstrated that use of Bonton can contribute to a potential reduction in the incidence of certain fractures, including those involving the spine and hip.

Additionally, Bonton is indicated to increase bone mass in men diagnosed with osteoporosis. This therapeutic approach is designed to provide support for the bone structure in individuals with this condition. The use of Bonton should be considered part of a patient's overall healthcare regimen to help maintain skeletal integrity.

Eligibility and Restrictions for Use

Eligibility Map: Official Regulatory Information

The eligibility for Bonton (Lorazepam) is strictly defined by regulatory authorities based on absolute contraindications, age, organ function, and physiological state.

Populations for whom use is contraindicated:

  • Patients with hypersensitivity to any benzodiazepine or formulation component.
  • Patients with acute narrow-angle glaucoma, severe respiratory insufficiency, severe hepatic insufficiency, or myasthenia gravis (as per international labeling).

Age-related eligibility rules:

  • Pediatric: Use for anxiety/insomnia is not established in children under 12 years (US label); use for Status Epilepticus (Injection) is permitted in children 2 years and older.
  • Older Adults (Geriatric): Use requires special caution, and the initial dose should be lower due to increased susceptibility to effects.

Condition-specific eligibility rules:

  • Organ Function: Severe hepatic insufficiency is a contraindication; impaired renal function requires caution and monitoring.
  • Comorbidities: Use is generally not recommended in patients with primary depressive disorder or psychosis (without antidepressant co-therapy) or in those with sleep apnea syndrome or a history of drug/alcohol dependence.

Pregnancy and lactation eligibility status:

  • Pregnancy: Use should be avoided as the medicine may cause neonatal sedation or withdrawal symptoms in the newborn.
  • Lactation: Not recommended as the substance is known to pass into human breast milk.

Connection to the overall eligibility profile: Official regulatory documents establish absolute exclusions for Bonton based on specific high-risk conditions, such as acute glaucoma or severe organ failure. Eligibility is then constrained by age, prohibiting unestablished pediatric use, and by physiological states like pregnancy, where use is actively advised against due to potential risks to the infant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The most clinically significant drug interactions involving Bonton are related to its breakdown by liver enzymes, specifically the Cytochrome P450 (CYP) enzymes CYP3A4 and CYP2C19. Bonton is a substrate for these enzymes, meaning other substances that inhibit or induce (speed up) their activity can alter Bonton's concentration in the body.

Interacting Products and Classes

Product Category Example Medicines Interaction Result/Classification
Strong or Moderate CYP3A4 Inhibitors Itraconazole, Diltiazem Contraindicated (should not be combined) due to significantly increased Bonton exposure.
CYP2C19 Inhibitors Fluconazole Requires dose reduction of Bonton to manage increased exposure.
Strong or Moderate CYP3A4 Inducers Rifampin Not Recommended; may lead to decreased Bonton concentrations and potential loss of effectiveness.

Key Interaction Requirements

Concomitant use of Bonton with strong or moderate CYP3A4 inhibitors is contraindicated by regulatory bodies, given the high risk of increased drug levels. For other interacting medicines, such as moderate CYP3A4 or CYP2C19 inhibitors, a maximum daily dose of Bonton must be adhered to. Individuals identified as CYP2C19 poor metabolizers face a naturally higher exposure risk, which is further exacerbated when combined with CYP3A4 or CYP2C19 inhibitors. These precautions are implemented to manage the predictable changes in Bonton's pharmacokinetics when co-administered with agents that affect its primary metabolic pathways.

Mechanism of Action

Targeted Molecular Action

Bonton initiates its action by selectively engaging specific receptor or enzyme targets located within key cellular systems. By acting as an inhibitor or antagonist, the drug modifies the activity of these primary targets, thus initiating or suppressing the early molecular steps in a signaling sequence.

Pathway Dampening and Signal Regulation

This targeted action leads to the modification of well-characterized molecular cascades associated with heightened physiological responses. Bonton modifies or reduces signaling intensity by altering the dynamics of transmission in defined neural or humoral pathways, specifically relevant in systems where rapid adjustment of activity is required.

Systemic Physiological Adjustment

The mechanism ultimately engages mechanisms that regulate overactive or dysregulated processes, influencing core mechanisms that shape the system's excitability. This results in altered kinetics that affect physiological responses and restricts the propagation of excessive mediator activity, resulting in physiological adjustments that characterize Bonton's mechanistic profile.

Dosage and Administration Information

The administration of Bonton, which contains the active substance Lorazepam, is governed by specific protocols. The medication is available for oral administration via tablets or concentrates and for parenteral administration via intravenous (IV) or intramuscular (IM) injection, which is typically reserved for acute, medically supervised settings.

Dosing is highly dependent on the condition being addressed. For routine anxiety management, the total daily adult dose is often between 2 mg and 3 mg, which is administered in divided doses throughout the day. Conversely, use for insomnia involves a single dose of 2 mg to 4 mg taken at bedtime. For acute, time-sensitive situations such as status epilepticus, the recommended IV dose is 4 mg, which may be repeated once after 5 to 10 minutes.

Proper use requires adherence to specific preparation rules. For the injection solution, the medicine must be diluted 1:1 with a compatible fluid before being administered. Similarly, the oral concentrate requires dilution with a liquid or soft food prior to consumption. A critical procedural constraint is the mandated adjustment for older or debilitated adults, who are typically started on a lower daily dose, often reduced by 50% from the standard adult starting regimen. Furthermore, Bonton is officially designated for short-term use only, and continuous therapy must conclude with a gradual dosage tapering to minimize potential discontinuation effects.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bonton (Lorazepam)


Evidence for Short-Term Relief of Anxiety Symptoms

The clinical evidence for The active ingredient in Bonton, Lorazepam, was studied in research exploring symptoms related to anxiety primarily comes from short-term randomized controlled trials (RCTs). These studies explored how symptoms evolved in the observed populations during the typically short treatment periods of one to four weeks. Research highlights changes measured during the study period, contributing to the understanding of short-term changes observed when the medication was used in research contexts involving fluctuating or unstable symptoms. Evidence for use exceeding four weeks is not well characterized by controlled trial data.

Evidence for Acute Agitation and Severe Nervousness

Research has explored the medication in contexts involving sudden, severe episodes of agitation mainly consisting of acute-phase RCTs and comparator trials. Studies monitored outcomes reflecting episodic or acute changes, including the time interval required to observe a state of calmness or reduced excitement. The findings describe group patterns related to observations of changes in agitation scores in the observed populations. The research describes patterns observed during the immediate, acute-phase response to intervention.

Evidence for Status Epilepticus (Seizure Cessation)

The evidence base for using Bonton in the acute emergency condition known as status epilepticus (continuous or recurrent seizures) is derived from controlled comparator trials. Research focused on the critical outcome of seizure cessation, monitoring observations of the continuous seizure activity stopping after intervention. While the data show patterns related to observed changes in acute seizure control, comparative evidence is sometimes lacking to definitively establish superior patterns of response over every other similar emergency medication.


What is Still Uncertain About Bonton's Evidence Base

A key uncertainty across the research landscape is that evidence is limited for use extending beyond a few weeks for chronic conditions like anxiety. Follow-up durations were limited in the foundational controlled trials. Research exploring short-term symptom changes does not provide individual predictions for long-term benefit. Additionally, comparative evidence is lacking for many potential long-term scenarios, and findings were sometimes inconsistent across studies, meaning the data available for certain groups or for extended use remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Bonton (FAQ)

Q: Does Bonton cause drowsiness or affect driving?

Official regulatory documents clearly state that Bonton can cause effects on the Central Nervous System (CNS), such as drowsiness, dizziness, and impaired coordination. Because of these common effects, official product information describes that operating heavy machinery or driving should be avoided until it is established that the medication does not impair performance.


Q: Can people take Bonton with over-the-counter pain relievers?

The official prescribing information focuses on interactions with medications that affect specific liver enzymes or that are CNS depressants. Official information states that a healthcare provider should be informed about all medicines and products being used, including over-the-counter pain relievers, so they can assess the possibility of any interaction.


Q: Does Bonton interact with alcohol?

Regulatory documents describe that alcohol should not be consumed while taking Bonton. Combining the two substances can significantly increase the sedative effects of the medicine, potentially leading to severe drowsiness, respiratory depression (slowed breathing), or coma.


Q: Can Bonton affect the results of common lab tests?

Official documentation indicates that the medicine has been associated with changes in certain laboratory tests. Specifically, reports detail findings of abnormal liver function tests, such as elevated transaminases, in some patients.


Q: What are the signs of a serious allergic reaction to Bonton?

Regulatory safety documentation describes symptoms of a potential hypersensitivity or allergic reaction. These signs may include a skin rash, swelling (angioedema), or difficulty breathing.


Q: Are there known interactions between Bonton and birth control pills?

The regulatory documents describe interactions with medicines that affect the liver enzymes responsible for breaking down Bonton. Official information describes that a healthcare provider should be informed about all current medications, including hormonal contraceptives (birth control pills), to check for potential effects on the level of either medication.


Q: What official health authorities have approved Bonton for use?

The active substance in Bonton is approved for use based on evidence reviewed by major global regulatory agencies. These include the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), which define its official uses.


Q: Can Bonton cause stomach upset or digestive issues?

Official product labeling includes stomach upset, nausea, and changes in appetite as possible adverse reactions. These effects are documented in official safety information but are generally less frequently observed than the very common side effects.


Q: Does Bonton interact with common herbal supplements like St. John's wort?

Regulatory documents warn that some products, including herbal supplements, can alter the function of specific liver enzymes (CYP3A4/2C19) that break down the drug. Official information states that a healthcare provider should be informed of any supplements being used to evaluate the potential for changes in Bonton's concentration.


Q: What happens if Bonton is stored in conditions that are too warm or humid?

Official documents require Bonton to be stored at a Controlled Room Temperature and kept away from excess heat and moisture. Storing the medicine outside of these specified conditions may potentially compromise the quality and stability of the tablets over the storage period.


Q: What is the general duration of the drug's effect after administration?

Pharmacokinetic data describes Bonton as a short-to-intermediate-acting agent. The drug's therapeutic effect is related to its half-life, which official reports describe as being approximately 12 to 16 hours for the active substance.


Q: Is Bonton considered a controlled substance?

Official government health authorities classify the active substance in Bonton as a Schedule IV controlled substance. This classification is given to medicines that have a recognized medical use but also a low potential for abuse or dependence relative to substances in other schedules.


Q: How long does Bonton typically take to start showing effects?

Pharmacokinetic data from official sources indicates that after oral administration, Bonton is rapidly absorbed into the body. The onset of the medicine's effects is typically noted within 30 minutes to one hour following ingestion.


Q: Are there any specific foods or supplements that should be avoided when using Bonton?

While official documents outline precautions regarding alcohol and certain medications, the regulatory documents do not list specific restrictions for most foods. The medicine's official information does not list specific food restrictions beyond alcohol and other medication interactions.


Q: Is it normal to feel a mild headache after starting Bonton?

Official prescribing information lists headache as a documented adverse reaction that may occur during the use of Bonton. This effect is generally listed among those that are less frequently observed than the very common side effects.


Q: Why do some users report difficulty sleeping when using Bonton?

Regulatory documents describe that while the medicine is primarily a sedative, insomnia and other paradoxical reactions have been reported. These effects, such as increased agitation or excitement, are described as rarely observed adverse events.


Q: What steps are generally advised if someone accidentally misses a dose of Bonton?

Official patient guidance outlines the typical process if a dose of Bonton is missed: the dose is generally not taken if the time for the next scheduled dose is approaching. Official information states that the prescribed schedule should be resumed, and patients are warned against taking a double dose.


Q: Is Bonton chemically related to any older, well-known medications?

Bonton is a product containing the active substance Lorazepam, which belongs to the benzodiazepine class of medications. This is a well-established pharmacological class that includes several older and recognized compounds used as calming and sedative agents.


Q: Does Bonton cause any changes in weight?

Official safety documentation for Bonton does not commonly list significant weight change as a frequent or very common adverse reaction. Studies have sometimes observed changes in appetite as a less common effect, but the overall patient response can vary.


Q: Is it necessary to take Bonton with food?

The regulatory documents describe that the tablet form of Bonton can generally be taken with or without food. However, the oral concentrate solution requires prior dilution with a liquid or soft food before ingestion.


Q: Does Bonton contain any common allergens like gluten or lactose?

Official product information documents are required to list the inactive ingredients used in the formulation. For example, the Bonton tablets may contain excipients like lactose. Patients with known allergies or intolerances should always check the official ingredients list.

How should Bonton be stored and disposed of?

Bonton (Lorazepam) tablets require specific handling to maintain stability and ensure safety. The medication must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The container must be kept tightly closed and stored away from excess heat and moisture. To protect the tablets, they should remain in the original container. A critical requirement is to keep Bonton out of the sight and reach of children in a secure, locked location.

For disposal, the drug must not be flushed down a sink or toilet. Unused or expired tablets should be taken to an official drug take-back program. If this is unavailable, the medication should be mixed with an unappealing substance, placed in a sealed bag, and discarded with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Bonton found in:

A-Z Index: